Category - Developments

Developments

SAB Biotherapeutics expanding pipeline for C. diff as DoD contract winds down

SAB Biotherapeutics (NASDAQ:SABS) will be discontinuing its work with the U.S. Department of Defense (DoD) under a prototype research and development agreement. The agreement, which was awarded in the summer of 2019...

August 10, 2022

Developments

Blue Water Vaccines in $10-million private placement

Blue Water Vaccines (NASDAQ:BWV) entered into definitive agreements with several healthcare-focused institutional investors for the purchase of 3,683,280 common shares of the company in a private placement priced at-the...

August 9, 2022

Developments

Sigyn Therapeutics to begin trading on OTCQB today

Shares of Sigyn Therapeutics (OTCQB:SIGY) will begin trading on the OTCQB Venture Exchange at the market open today. The company’s securities, which previously traded on the OTC Pink Market, will continue to trade...

August 3, 2022

Developments

PharmaJet partner, Scancell, to use needle-free delivery with melanoma vaccine

PharmaJet partner, Scancell, will include PharmaJet’s needle-free delivery system in a Phase 2 clinical study of a vaccine for treatment of patients with advanced melanoma. Scancell’s immunotherapy platform uses the...

August 2, 2022

Developments

Qualigen posts positive readout in triple negative breast cancer in vivo model

Qualigen Therapeutics (NASDAQ:QLGN) completed its in vivo efficacy analysis of QN-247 in solid tumors, with data demonstrating robust efficacy and no safety signals in a triple negative breast cancer (TNBC) model...

August 2, 2022

Developments

NeuroSense, NeuraLight in pact to detect ALS oculometric biomarkers

NeuroSense Therapeutics (NASDAQ:NRSN) and closely-held NeuraLight are collaborating to advance the science of digital biomarkers in the detection and monitoring of neurological diseases, including amyotrophic lateral...

July 28, 2022

Developments

NervGen NVG-291-R posts significant preclinical functional repair from stroke

The University of Cincinnati and Case Western Reserve University published a pioneering preclinical study in the peer-reviewed scientific journal, Cell Reports, demonstrating that NervGen Pharma‘s (TSXV:NGEN;...

July 28, 2022

Developments

Palisade Bio screens first patient in Phase 3 bowel function trial

Palisade Bio (NASDAQ:PALI) screened the first patient in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. “With the first U.S...

July 27, 2022

Developments

180 Life Sciences, U of Oxford to study post operative delirium

A team led by researchers at University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) in the U.K. to conduct a feasibility trial to investigate whether anti-tumor...

July 27, 2022

Developments

VistaGen fails Phase 3 trial in social anxiety disorder

VistaGen Therapeutics’ (NASDAQ:VTGN) topline results from its PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder did not achieve its primary endpoint, as...

July 22, 2022

Category - Developments

Subscribe